Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax (APG-2575) Alone or in Combination With HHT or AZA in R/R AML and Related Myeloid Malignancies
NCT04501120Phase 2Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Sep 2020
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lisaftoclax in acute myeloid leukemia (AML), Myeloid malignancy, mixed phenotype acute leukemia (MPAL), chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome (MDS), sponsored by Ascentage Pharma. Started Sep 2020; status: recruiting.
02
Drugs
lisaftoclax
03
Conditions
acute myeloid leukemia (AML)Myeloid malignancymixed phenotype acute leukemia (MPAL)chronic myelomonocytic leukemia (CMML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04501120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04501120.